- Home
- IMMX vs EEA Comparison
IMMX vs EEA Comparison
Compare IMMX & EEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- EEA
- Stock Information
- Founded
- IMMX 2014
- EEA 1986
- Country
- IMMX United States
- EEA Germany
- Employees
- IMMX N/A
- EEA N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- EEA Trusts Except Educational Religious and Charitable
- Sector
- IMMX Health Care
- EEA Finance
- Exchange
- IMMX Nasdaq
- EEA Nasdaq
- Market Cap
- IMMX 61.1M
- EEA 67.9M
- IPO Year
- IMMX 2021
- EEA N/A
- Fundamental
- Price
- IMMX $2.65
- EEA $10.28
- Analyst Decision
- IMMX Strong Buy
- EEA
- Analyst Count
- IMMX 1
- EEA 0
- Target Price
- IMMX $7.00
- EEA N/A
- AVG Volume (30 Days)
- IMMX 137.1K
- EEA 9.2K
- Earning Date
- IMMX 08-11-2025
- EEA 01-01-0001
- Dividend Yield
- IMMX N/A
- EEA 1.92%
- EPS Growth
- IMMX N/A
- EEA N/A
- EPS
- IMMX N/A
- EEA N/A
- Revenue
- IMMX N/A
- EEA N/A
- Revenue This Year
- IMMX N/A
- EEA N/A
- Revenue Next Year
- IMMX N/A
- EEA N/A
- P/E Ratio
- IMMX N/A
- EEA N/A
- Revenue Growth
- IMMX N/A
- EEA N/A
- 52 Week Low
- IMMX $1.26
- EEA $7.45
- 52 Week High
- IMMX $3.00
- EEA $9.26
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- EEA 70.14
- Support Level
- IMMX $2.16
- EEA $9.85
- Resistance Level
- IMMX $2.80
- EEA $10.45
- Average True Range (ATR)
- IMMX 0.17
- EEA 0.12
- MACD
- IMMX 0.04
- EEA 0.02
- Stochastic Oscillator
- IMMX 80.00
- EEA 85.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.